Objective To analyze the effectiveness and safety of intravenous immunoglobulin (IVIG)
given in routine care to patients with systemic sclerosis (SSc). Methods A retrospective …

Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA).
Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in …

Objective To compare the efficacy and safety of TCZ in monotherapy (TCZ MONO) vs.
combined with conventional immunosuppressive drugs (TCZ COMBO) in Giant Cell Arteritis …

Background: Visual involvement is the most feared complication of giant cell arteritis (GCA).
Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and …

Objective. To determine if patients with the predominant extracranial largevessel vasculitis
(LVV) pattern of giant cell arteritis (GCA) have a distinctive HLA-B association, different from …

Objective Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis
(GCA). There is general agreement on the initial/maintenance dose, duration of TCZ therapy …

Objective To investigate the human leukocyte antigen (HLA) association with anti-
synthetase syndrome (ASSD). Methods We conducted the largest immunogenetic HLA …

Objective To determine whether giant cell arteritis (GCA) patients with the typical pattern of
cranial ischemic manifestations and those with the extracranial large-vessel-vasculitis (LVV) …

Background Oral and/or genital aphthous ulcers are the most common symptoms of Behçets
disease (BD), and are often refractory to conventional treatment. The inhibitor of …

Objectives To determine whether functional vascular endothelial growth factor (VEGF)
polymorphisms influence the expression of the clinical phenotype of giant cell arteritis …